<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690585</url>
  </required_header>
  <id_info>
    <org_study_id>2011/123/HP</org_study_id>
    <nct_id>NCT01690585</nct_id>
  </id_info>
  <brief_title>Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65</brief_title>
  <acronym>FerHem</acronym>
  <official_title>Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The upper and lower gastrointestinal bleeding, not related to portal hypertension, is a&#xD;
      common disorder in the elderly. Indeed, in 1996, in a French study, the median age of&#xD;
      patients hospitalized for upper gastrointestinal bleeding was 68. During the same period in&#xD;
      the studies reported in English the median age was 71. If epidemiological data concerning&#xD;
      lower gastrointestinal bleeding are rare, the average age of hospitalized patients varies&#xD;
      from 63 to 77 depending on the study. Due to improvement in endoscopic haemostatic procedures&#xD;
      and current resuscitation methods, gastrointestinal bleeding prognosis has greatly improved,&#xD;
      whereas anaemia related to a bleeding episode remains a frequent complication of&#xD;
      gastrointestinal bleeding in elderly patients.&#xD;
&#xD;
      Among elderly patients over 65, the prevalence of anaemia varies from 8 to 44% depending on&#xD;
      the criteria used and populations studied. The occurrence of a bleeding episode can either&#xD;
      induce anaemia or exacerbate pre-existing anaemia. Physicians in charge of gastrointestinal&#xD;
      bleeding are often unaware of anaemic consequences in the elderly patients which can often be&#xD;
      serious. Various studies have shown that anaemia increases morbidity and mortality rates in&#xD;
      the elderly. Life expectancy is independently significantly lower for anaemic patients over&#xD;
      65, than for non-anaemic subjects. Anaemia is also a risk factor for the occurrence of&#xD;
      cardiovascular and neurological complications, impairment in cognitive function and increased&#xD;
      risk of falling.&#xD;
&#xD;
      Iron deficiency and anaemia induced by bleeding episodes in patients over 65 hospitalized for&#xD;
      upper or lower gastrointestinal bleeding should be corrected rapidly and effectively.&#xD;
      Currently, the cost and risks of infection or cardiovascular-related complications of&#xD;
      transfusions lead to limiting red blood cell transfusion with a goal average of 9 g/dL&#xD;
      haemoglobin. It is also necessary to develop alternatives to massive transfusions. The&#xD;
      correction of iron deficiency promotes erythropoiesis and can quickly correct anaemia.&#xD;
&#xD;
      In clinical practice, the effectiveness of iron intake by the oral route is limited by the&#xD;
      frequent occurrence of significant gastrointestinal side effects that limit patient&#xD;
      compliance and limited absorption necessitating prolonged treatment to correct iron&#xD;
      deficiency.&#xD;
&#xD;
      The black colour of stools caused by taking oral iron supplements also makes it difficult to&#xD;
      detect a possible recurrence of bleeding after hospitalization.&#xD;
&#xD;
      The prescription of intravenous iron seems more suitable for a rapid and complete correction&#xD;
      of iron deficiency after gastrointestinal bleeding. The main objective of our study is to&#xD;
      evaluate efficacy of intravenous iron for the correction of anaemia, measured by haemoglobin&#xD;
      at week 6 (W6) in patients aged over 65, after gastrointestinal bleeding. Secondary&#xD;
      objectives were to assess the speed of anaemia correction, the tolerance of intravenous iron&#xD;
      supplementation, the rate of re-hospitalization within 6 months after discharge and patients&#xD;
      quality of life. This is a prospective multicenter randomized study versus placebo. After&#xD;
      obtaining informed consent, all patients aged over 65 admitted with upper or lower&#xD;
      gastrointestinal bleeding, with successful outcome, not related to portal hypertension,&#xD;
      responsible for persistent anaemia (definition: Hb &lt; 11 g / dL) after hospitalization will be&#xD;
      included in the study. Patients will be treated for their bleeding event in the usual manner&#xD;
      of each centre with target for transfusion of 9 g / dL haemoglobin. The absence of external&#xD;
      bleeding and haematocrit and/or constant haemoglobin levels will be considered as the end of&#xD;
      bleeding.&#xD;
&#xD;
      Day 1 was arbitrarily defined as the day the patient left hospital. The protocol at Day - 1&#xD;
      included: obtaining informed consent of the patient, determination of iron and ferritin blood&#xD;
      levels and complete blood count. and randomization intravenous iron injection , (Ferinject)&#xD;
      versus Placebo. Intravenous iron injection will be performed at Day 0. A complete blood count&#xD;
      will be performed at week 6 and month 6. Patients will be reviewed in consultation at week 6&#xD;
      and at month 6 to obtain related intercurrent events and assess their quality of life.&#xD;
&#xD;
      The results of this study could lead to changes in the care of older patients hospitalized&#xD;
      for gastrointestinal bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the tolerance of intravenous iron supplementation</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of Adverse Event (AE) and Serious Adverse Event(SAE) occurence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the tolerance of intravenous iron supplementation</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of Adverse Event (AE) and Serious Adverse Event(SAE) occurence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-hospitalization rate</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Ferinject 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous administration of 250 ml of sodium chlorure 0.9 %</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject 1000 mg</intervention_name>
    <arm_group_label>Ferinject 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chlorure 0,9 %</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged over 65 hospitalized for upper or lower GI bleeding with positve outcome&#xD;
             during hospitalization without surgery, and with persistent anaemia (Hb &lt;11g/dL),&#xD;
&#xD;
          2. Signed informed consent,&#xD;
&#xD;
          3. Patients with National Health Insurance,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled haemorrhage defined by any new externalizing and / or a decrease of&#xD;
             haemoglobin and haematocrit levels,&#xD;
&#xD;
          2. GI bleeding related to portal hypertension or malignancy,&#xD;
&#xD;
          3. The absence of anaemia,&#xD;
&#xD;
          4. Cancer evolution,&#xD;
&#xD;
          5. Patient under guardianship, curatorship or unable to supply consent,&#xD;
&#xD;
          6. Iron overload,&#xD;
&#xD;
          7. History of asthma&#xD;
&#xD;
          8. History of eczema&#xD;
&#xD;
          9. Hypersensitivity to any component&#xD;
&#xD;
         10. Decompensated liver cirrhosis&#xD;
&#xD;
         11. Infection during treatment or uncontrolled infection 12 Rheumatoid arthritis&#xD;
&#xD;
        13. Acute renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume SAVOYE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI le Raincy Montfermeil</name>
      <address>
        <city>Le raincy</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH du havre</name>
      <address>
        <city>Montivilliers</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Montélimar</name>
      <address>
        <city>Montélimar</city>
        <zip>26216</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2012</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

